Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01200342 · ClinicalTrials.gov registry record · Phase 2
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01200342: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01200342 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01200342, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Genasense
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01200342
The ClinicalTrials.gov registry entry for NCT01200342 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT01200342 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01200342 about?
NCT01200342 is a clinical study titled "Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma". The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
What is the current status of trial NCT01200342?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2010-12. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01200342?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Genasense (DRUG).
Who is sponsoring clinical trial NCT01200342?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.